Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer

Journal of Nuclear Medicine

Volumn 56, Issue 6, 2015, Pages 914-920

  Benesová, Martina ^a   Schäfer, Martin ^a   Bauder Wüst, Ulrike ^a   Afshar Oromieh, Ali ^b   Kratochwil, Clemens ^b   Mier, Walter ^b   Haberkorn, Uwe ^a,b   Kopka, Klaus ^a   Eder, Matthias ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Endoradiotherapy; PET imaging; Prostate cancer; PSMA; Theranostic radiopharmaceuticals

Indexed keywords

GALLIUM 67; GALLIUM 68; LUTETIUM 177; PROSTATE SPECIFIC MEMBRANE ANTIGEN 617; PROTEIN INHIBITOR; TETRAXETAN; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; CHELATING AGENT; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; COMPETITIVE BINDING ASSAY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDORADIOTHERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMAGE QUALITY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; LNCAP CELL LINE; LYMPH NODE METASTASIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE CANCER; RADIOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; DIAGNOSTIC USE; MASS SPECTROMETRY; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION;

EID: 84930364730     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.147413     Document Type: Article

References (31)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-1403.
2. Scher B, Seitz M, Albinger W, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34: 45-53.
3. Reske SN, Blumstein NM, Neumaier B, et al. Imaging prostate cancer with 11Ccholine PET/CT. J Nucl Med. 2006;47:1249-1254.
4. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR. 2012;199:278-291.
5. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL. New horizons in prostate cancer imaging. Eur J Radiol. 2009;70:212-226.
6. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-2041.
7. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807-1811.
8. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227-230.
9. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932-6940.
10. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022-4028.
11. Banerjee SR, Pullambhatla M, Byun Y, et al. 68Ga-labeled inhibitors of prostatespecific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333-5341.
12. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008;38:358-366.
13. Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a 124I/131I labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
14. Wester HJ, Schottelius M, Scheidhauer K, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging. 2003;30:117-122.
15. Liu T, Nedrow-Byers JR, Hopkins MR, Berkman CE. Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorg Med Chem Lett. 2011;21:7013-7016.
16. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517.
17. Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
18. Schuhmacher J, Maier-Borst W. A new Ge-68/Ga-68 radioisotope generator system for production of Ga-68 in dilute HCl. Int J Appl Radiat Isot. 1981;32:31-36.
19. Schäfer M, Bauder-Wüst U, Leotta K, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for Ga-68-PET imaging. Eur J Nucl Med Mol Imaging Res. 2012;2:23-33.
20. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
21. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
22. Eder M, Neels O, Müller M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7:779-796.
23. Shelley M, Harrison C, Coles B, Stafforth J,Wilt T, Mason M. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. 2006;4: CD005247.
24. Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D. What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging. 2007;34:1897-1901.
25. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):13S-17S.
26. Zhang AX, Murelli RP, Barinka C, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2010;132:12711-12716.
27. Antunes P, Ginj M, Walter MA, Chen J, Reubi JC, Maecke HR. Influence of different spacers on the biological profile of a DOTA2somatostatin analogue. Bioconjug Chem. 2007;18:84-92.
28. Kane RS. Thermodynamics of multivalent interactions: influence of the linker. Langmuir. 2010;26:8636-8640.
29. Maung J, Mallari JP, Girtsman TA, et al. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem. 2004;12:4969-4979.
30. Behe M, Alt K, Deininger F, et al. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo. 2011;25:55-59.
31. Kratochwil C, Giesel FL, Eder M, et al. [177Lu]lutetium-labelled PSMA ligandinduced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987-988.